2024. Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . SKIN The Journal of Cutaneous Medicine. 8, 4 (Jul. 2024), s405. DOI:https://doi.org/10.25251/skin.8.supp.405.